1034769-73-7

Basic information

• Product Name: 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine
• CAS NO: 1034769-73-7
• Molecular Weight: 362.729
• Mol File: 1034769-73-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine(1034769-73-7)
• EPA Substance Registry System: 5-bromo-4-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine(1034769-73-7)

Safety Data

• Hazardous Substances Data: 1034769-73-7(Hazardous Substances Data)

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 22276-95-5 5-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 

Downstream Products

• 1351533-44-2 tert-butyl (4-(5-(3-(hydroxymethyl)phenyl)-7-((2-(trimethylsilyl)-ethoxy)-methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholin-2-yl)methyl-carbamate 
• 1034769-08-8 3-(4-(2-(aminomethyl)morpholino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile 
• 1034769-06-6 (3-(4-(2-(aminomethyl)morpholino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)methanol 
• 1351533-43-1 tert-butyl (4-(5-(3-cyanophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholin-2-yl)methylcarbamate 
• 1351533-45-3 tert‐butyl ((4‐(5‐(3‐cyanophenyl)‐7H‐pyrrolo[2,3‐d]pyrimidin‐4‐yl)morpholin‐2‐yl)methyl)carbamate 
• 1351533-46-4 C₂₃H₂₉N₅O₄ 

Relevant articles and documents

PYRROLOPYRIMIDINE ITK INHIBITORS

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

IRAK4 kinase inhibitor and preparation method thereof

The invention provides a compound with a general formula I, and a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof, wherein the compound is an IRAK4 kinase inhibitor and can be used for pre

Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing

Pyrazolopyridine inhibitors with low micromolar potency for CHK1 and good selectivity against CHK2 were previously identified by fragment-based screening. The optimization of the pyrazolopyridines to a series of potent and CHK1-selective isoquinolines demonstrates how fragment-growing and scaffold morphing strategies arising from a structure-based understanding of CHK1 inhibitor binding can be combined to successfully progress fragment-derived hit matter to compounds with activity in vivo. The challenges of improving CHK1 potency and selectivity, addressing synthetic tractability, and achieving novelty in the crowded kinase inhibitor chemical space were tackled by multiple scaffold morphing steps, which progressed through tricyclic pyrimido[2,3-b] azaindoles to N-(pyrazin-2-yl)pyrimidin-4-amines and ultimately to imidazo[4,5-c]pyridines and isoquinolines. A potent and highly selective isoquinoline CHK1 inhibitor (SAR-020106) was identified, which potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice. (Figure presented)